MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-24-2026
Corcept Therapeutics Incorporated Net Income 2011-2026 | CORT
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Corcept Therapeutics Incorporated
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 99.7 M | 141 M | 106 M | 101 M | 113 M | 106 M | 94.2 M | 75.4 M | 129 M | 8.14 M | -6.41 M | -31.4 M | -46 M | -38 M | -32.4 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 141 M | -46 M | 54.6 M |
Quarterly Net Income Corcept Therapeutics Incorporated
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 19.7 M | 35.1 M | 20.5 M | 47.2 M | 35.5 M | 27.8 M | 31.4 M | 27.5 M | 15.9 M | - | 34.6 M | 27.4 M | 22.8 M | - | 30.5 M | 26.5 M | 23.5 M | 26 M | 21.6 M | 28.3 M | 30.1 M | 29.4 M | 26.3 M | 20.2 M | 18.3 M | 22 M | 17.7 M | 18.2 M | 17.5 M | 98.3 M | 13.8 M | 12.6 M | 4.39 M | 4.6 M | 2.58 M | 977 K | -19 K | 959 K | -601 K | -1.94 M | -4.83 M | -3.9 M | -6.01 M | -7.55 M | -13.9 M | -11.1 M | -10.9 M | -11.9 M | -12.1 M | -11.1 M | -8.29 M | -7.6 M | -11 M | -9.94 M | -6.44 M | -8.88 M | -7.1 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 98.3 M | -13.9 M | 12.4 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Biotechnology industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-514 M | - | 2.43 % | $ 254 M |  Germany |
 |
Celldex Therapeutics
CLDX
|
-259 M | $ 34.86 | 2.95 % | $ 2.32 B |  USA |
 |
Alterity Therapeutics Limited
ATHE
|
-12.8 M | $ 4.3 | 8.31 % | $ 10.3 B |  Australia |
 |
Adverum Biotechnologies
ADVM
|
-131 M | - | - | $ 86.2 M | USA |
 |
Akouos
AKUS
|
-86.7 M | - | 0.23 % | $ 488 M | USA |
 |
I-Mab
IMAB
|
-1.47 B | - | - | $ 866 M |  China |
 |
Citius Pharmaceuticals
CTXR
|
-39.4 M | $ 0.87 | 2.3 % | $ 5.85 M | USA |
 |
AlloVir
ALVR
|
-43.4 M | - | 4.14 % | $ 49.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
603 M | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
67.3 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-31.2 M | - | -13.47 % | $ 169 M | France |
 |
Akari Therapeutics, Plc
AKTX
|
-17.3 M | $ 5.51 | 7.65 % | $ 371 B |  Britain |
 |
Aligos Therapeutics
ALGS
|
-24.2 M | $ 6.71 | -12.4 % | $ 66.3 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
314 M | $ 306.52 | -4.25 % | $ 40.2 B | USA |
 |
Allakos
ALLK
|
-186 M | - | - | $ 28.6 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-8.09 M | - | -1.52 % | $ 24.7 M | USA |
 |
Forte Biosciences
FBRX
|
-69.4 M | $ 32.69 | 3.99 % | $ 423 M | USA |
 |
Midatech Pharma plc
MTP
|
-5.46 M | - | -18.52 % | $ 27.3 M | Britain |
|
Applied Molecular Transport
AMTI
|
-126 M | - | - | $ 10.1 M | USA |
 |
Galectin Therapeutics
GALT
|
-30.8 M | $ 2.43 | 7.52 % | $ 155 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
98.1 M | $ 22.73 | 4.22 % | $ 1.06 B | USA |
 |
Applied Therapeutics
APLT
|
-120 M | - | - | $ 8.42 M | USA |
 |
Galapagos NV
GLPG
|
-103 M | $ 29.24 | 1.3 % | $ 2.69 B |  Belgium |
 |
Grifols, S.A.
GRFS
|
265 M | $ 8.7 | 1.16 % | $ 6.83 B |  Spain |
 |
GT Biopharma
GTBP
|
-28.4 M | $ 0.38 | -4.21 % | $ 2.1 M | USA |
 |
BioNTech SE
BNTX
|
10.3 B | $ 104.28 | 2.11 % | $ 27.2 B | Germany |
 |
Aptinyx
APTX
|
-64.8 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
-76.3 M | - | -13.39 % | $ 1.45 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
72.9 M | - | - | - |  Russia |
 |
Advaxis
ADXS
|
-48.1 M | - | -9.65 % | $ 45.9 M | USA |
 |
Hoth Therapeutics
HOTH
|
-12.5 M | $ 0.72 | -2.61 % | $ 9.94 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-9.83 M | $ 3.04 | -1.17 % | $ 5 M |  Israel |
 |
Aeterna Zentaris
AEZS
|
-8.37 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
-19.2 M | - | -10.17 % | $ 12.2 K | USA |
 |
BioXcel Therapeutics
BTAI
|
-69.9 M | $ 1.17 | 8.88 % | $ 14.3 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-155 M | - | - | $ 1.01 B | USA |
 |
InflaRx N.V.
IFRX
|
-45.6 M | $ 1.55 | 28.75 % | $ 152 M | Germany |
 |
Akebia Therapeutics
AKBA
|
-5.34 M | $ 1.43 | 5.56 % | $ 368 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-38 M | - | - | $ 7.46 M | Israel |
 |
Applied Genetic Technologies Corporation
AGTC
|
-18.4 M | - | - | $ 26.5 M | USA |
 |
Immutep Limited
IMMP
|
-29.9 M | $ 0.6 | 4.21 % | $ 1.08 B | Australia |
 |
Aquestive Therapeutics
AQST
|
-83.8 M | $ 4.34 | 1.76 % | $ 464 M | USA |
 |
AstraZeneca PLC
AZN
|
115 M | - | - | $ 96.9 B | Britain |
 |
Arcutis Biotherapeutics
ARQT
|
-16.1 M | $ 24.54 | 1.45 % | $ 3.12 B | USA |
 |
Burford Capital Limited
BUR
|
172 M | $ 4.91 | 5.14 % | $ 792 M | Britain |
 |
AIkido Pharma
AIKI
|
-22.4 M | - | 1.93 % | $ 17.4 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
-10.3 M | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
84.9 M | - | -4.8 % | $ 255 M | USA |
 |
Cabaletta Bio
CABA
|
-168 M | $ 3.32 | -5.68 % | $ 334 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-288 M | $ 1.65 | 2.17 % | $ 439 M | Britain |